PSYCHEDELIC DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Psychedelic Drugs Market Size and Trends

The global psychedelic drugs market is estimated to reach at USD 3.88 Bn in 2025 and is expected to hold USD 9.60 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 13.8% from 2025 to 2032. 

To learn more about this report, Download Free Sample

Key Takeaways

• Based on Drug Type, Psilocybin segment is projected to account for 32.6% of the global market in 2025, owing to its significant therapeutic potential and increasing acceptance in mental health treatment.
• By Application insights, Mental Health Disorders division is expected to account 32.6% share of the market in 2025, with depression being the dominant application area.
• Based on Distribution Channel, Hospital Pharmacy is expected to hold 42.6% share in 2025, owing to the growth of specialized treatment facilities offering psychedelic therapy. 
• By Route of Administration, Oral sector is poised to hold highest shares in the global market during the forecast period.
• Based on Region, North America is set to dominate the global market with a 39.7% share in 2025.

Market Overview

The global psychedelic drugs market is witnessing high growth owing to increasing research activities involving psychedelic drugs for treating mental health disorders. Psychedelic drugs such as psilocybin, 3,4-methylenedioxymethamphetamine (MDMA), and ketamine. These drugs are being examined in clinical trials and have shown potential for treating depression, post-traumatic stress disorder (PTSD), opioid addiction, and other mental health issues.

Current Events and their Impact on the Psychedelic Drugs Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Psychedelic Drugs Market Insights, By Drug Type – High efficacy drives demand for psilocybin

Psilocybin is emerging as a dominant segment with 32.6% share in 2025. This is because it has a lot of therapeutic potential and is becoming more widely used in mental health treatment. Studies have shown that these drugs are used to treat conditions such as depression, anxiety, and PTSD.

For instance, in October 2022, Zylorion Health Inc., announced the filing of a composition of matter patent with the United States Patent and Trademark Office ("USPTO") for the Company's novel second-generation lead psychedelic compound.

Psychedelic Drugs Market Insights, By Application – Application in mental health disorders leads as depression prevalence increases

In terms of application, the mental health disorders segment is projected to hold 32.6% share in 2025. This prominence is attributable to rising incidence of depression globally and the increasing acknowledgment of psychedelics.

Psychedelic Drugs Market Insights, By Distribution Channel – The growth of specialized treatment facilities drives distribution through hospital pharmacy

In terms of Distribution Channel, Hospital Pharmacy segment is estimated to hold market share of 42.6% in 2025. This is owing to the growth of specialized treatment facilities offering psychedelic therapy. Traditionally psychedelic drugs were accessible only through underground channels or unauthorized sources due to legal restrictions.

Psychedelic Drugs Market Insights, By Route of Administration

In terms of Route of Administration, oral segment is poised to lead the psychedelic drugs market during the forecast period, owing to growing demand for no-invasive treatment options globally.

Regional Insights

To learn more about this report, Download Free Sample

North America Psychedelic Drug Market Analysis & Trends

North America is expected to acquire the largest share in the psychedelic drugs market by holding 39.7% shares in 2025. This can be attributed to the strong presence of major players, growing acceptability of psychedelic-assisted therapies, favorable reimbursement policies, and active government support for research.

Asia Pacific Psychedelic Drug Market Analysis & Trends

The Asia pacific region exhibits the fastest growth rates fueled by increasing mental health burden, growing awareness about psychedelic therapies, and strategic efforts by industry players and research institutes to introduce these therapies. Multiple clinical research collaborations focusing on psychedelic drugs have accelerated Asia Pacific’s therapeutic landscape.

For instance, in May 2024, Novotech has signed a Memorandum of Understanding (MOU) with New Zealand Clinical Research (NZCR) for psychedelic drugs, which is further proliferating the psychedelic drugs market share.

Psychedelic Drugs Market Outlook for Key Countries

The U.S. Psychedelic Drug Market Analysis & Trends

The U.S. hold prominent share in the psychedelic drugs market due to extensive research and clinical trials. In April 2023, the U.S. Food and Drug Administration provided therapy designation to psilocybin for major depressive disorder. This reflects growing acceptance and regulatory support for psychedelic treatments.

Canada Psychedelic Drug Market Analysis & Trends

Canada is rapidly advancing in the psychedelic space, owing to government allowing psilocybin use for therapeutic purposes. In June 2023, the Canadian Cannabis Survey reported a 30.5% increase in approved clinical trials for psychedelics, which is expected to drive the market growth.

Japan Psychedelic Drug Market Analysis & Trends

Japan is beginning to explore the therapeutic potential of psychedelics, with recent studies indicating a growing interest in their use for mental health treatment. In May 2025, Japanese pharmaceutical giant Otsuka announced a joint research agreement with Keio University aimed at building infrastructure for “the social implementation of psychedelics in Japan.

China Psychedelic Drug Market Analysis & Trends

China's increasing mental health issues are driving interest in psychedelic therapies. In June 2024, report from National Task Force on Mental Health and well-being of Medical Students highlighted a 25.5% rise in mental health disorders, prompting the exploration of alternative treatments, including psychedelics.

India Psychedelic Drug Market Analysis & Trends

India's rising mental health challenges are creating opportunities for psychedelic therapies. For instance, in September 2024, Tata Institute of Fundamental Research (TIFR) study, in collaboration with Cornell, Yale, and Columbia, identified the ventral hippocampus as key in reducing anxiety through psychedelics.

Market Concentration and Competitive Landscape

To learn more about this report, Download Free Sample

Psychedelic Drugs Industry News

• In June 2025, the Ohio State University's Center for Psychedelic Drug Research and Education (CPDRE) launched the Certificate in Interdisciplinary Psychedelic Studies (CIPS), the first university-level program tailored for non-clinical learners seeking accessible psychedelic education.
• In June 2024, CU Denver Center is launched for Psychedelic Research at the University of Colorado Denver. The center is dedicated to improving the quality of life of people by studying the possible benefits psychedelic drugs may have in treating a range of mental, emotional, neurologic, and other health conditions, as well as their potential use for late-stage cancer, and chronic, debilitating diseases.
• In June 2023, the U.S. Food and Drug Administration issued its first draft guidance to aid researchers in designing clinical trials for psychedelic drugs. The guidance addresses key considerations for evaluating these compounds' safety and effectiveness in treating conditions like depression, PTSD, and substance use disorders.

Key Takeaways from Analyst

• The global psychedelic drugs market has significant growth potential over the next decade. Decriminalization and legalization of psilocybin and other compounds for medical use in jurisdictions like Oregon, Canada and several countries in Europe will drive opportunities. Psychedelic-assisted therapy has shown promise in treating depression, anxiety, PTSD, and other mental health conditions which have a large addressable patient pool.

North America currently dominates the space and is expected to maintain lead. However, Europe is witnessing increased research into medical applications of LSD, MDMA, and ketamine. This may position the region as an emerging market for psychedelic drugs. In Latin America, markets like Mexico and Brazil could emerge as major suppliers as well as consumers with growing awareness.

Market Report Scope

Psychedelic Drugs Market Report Coverage

Market Dynamics

Market Driver - Increasing acceptance of psychedelic therapy for mental health treatment

The role of psychedelic substances in treating mental health conditions such as depression, anxiety, and addiction has seen growing acceptance in recent years. While psychedelics were previously seen as expressions of counterculture, newer scientific research has pointed to their potential therapeutic benefits when administered in clinical settings.

For instance, in January 2023, according to the National Institutes of Health, several regions have begun to reconsider the legal status of psychedelics for therapeutic use. For example, Oregon became the first state in the U.S. to legalize psilocybin therapy.

Market Opportunity- Expansion of therapeutic applications in mental health disorders

The global psychedelic drugs market has enormous potential opportunity with the expansion of therapeutic applications of these compounds for various mental health disorders. Currently approved psychedelic-assisted therapies such as psilocybin for treatment-resistant depression have shown very promising results.

Key Stakeholders of Market

What Growth in the Global Psychedelic Drugs Market Mean for Different Stakeholders?

The psychedelic drugs market has multiple players with varied designations and offers multiple opportunities based on their scope of operations.

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Market Segmentation

• By Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
• Gamma Hydroxybutyric Acid (GHB)
• Ketamine
• Psilocybin
• Lysergic Acid Diethylamide (LSD)
• 3,4-Methylenedioxymethamphetamine (MDMA)
• Other Drug Types (Mescaline, etc.)
• By Application Insights (Revenue, USD Bn, 2020 - 2032)
• Mental Health Disorders
• Depression
• Anxiety
• PTSD (Post-Traumatic Stress Disorder)
• Substance Use Disorders
• Neurological Disorders
• Alzheimer’s Disease
• Parkinson’s Disease
• Pain Management:
• Chronic Pain
• Migraines
• Other Applications:
• Obsessive-Compulsive Disorder (OCD)
• Others (Opiate Addiction, etc.)
• By Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• By Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
• Oral
• Intravenous
• Inhalation
• Intranasal
• Others (Rectal)
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• MindMed
• Compass Pathways
• Cybin Inc.
• Atai Life Sciences
• Field Trip Health Ltd.
• Havn Life Sciences
• Revive Therapeutics
• NeonMind Biosciences
• Numinus Wellness
• PharmaTher Holdings Ltd.
• Jazz Pharmaceuticals
• Seelos Therapeutics
• NRx Pharmaceuticals Inc.
• Psyched Wellness Ltd.
• Silo Wellness

Sources

Primary Research Interviews

• Pharmaceutical Company Executives
• Clinical Research Organizations (CROs) Representatives
• Healthcare Professionals and Psychiatrists
• Regulatory Affairs Specialists
• Others

Databases

• FDA Orange Book Database
• PHRMA Database
• Others

Magazines

• Psychedelic Medicine Magazine
• Nature Medicine
• Drug Discovery & Development
• Pharmaceutical Executive
• Others

Journals

• Journal of Psychopharmacology
• Psychedelic Medicine Research
• Nature Neuroscience
• Others

Newspapers

• The Wall Street Journal
• Financial Times
• Reuters Health News
• Bloomberg Healthcare
• Others

Associations

• Multidisciplinary Association for Psychedelic Studies (MAPS)
• American Psychiatric Association (APA)
• International Association for the Study of Pain (IASP)
• Pharmaceutical Research and Manufacturers of America (PhRMA)
• Others

Public Domain Sources

• FDA Drug Approvals and Database
• National Institute of Mental Health (NIMH)
• World Health Organization (WHO) Reports
• European Medicines Agency (EMA) Publications
• Others

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 8 years